Login to Your Account

TGA move to regulate autologous stem cell therapies is long overdue, industry says

By Tamra Sami
Staff Writer

Wednesday, November 8, 2017

PERTH, Australia – Companies in the regenerative medicine space have long been pushing the Therapeutic Goods Administration (TGA) to regulate autologous cell and tissue products in Australia, and they strongly support the agency's moves toward stronger regulation.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription